Follows people with metastatic prostate cancer treated with Pluvicto in Korea
Observes safety of Pluvicto in adults with advanced prostate cancer in Korea.
Plain-language title generated from the registry record
Registry title: Post Marketing Study on Pluvicto in Korea
Key facts
- Where
- Busan, Gyeonggi-do, Jeollanam, Seongnam-si, Seoul, and Suwon, South KoreaSee the 6 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 100 years old?
Source: NCT06514521, who can take part
Where in South Korea
- BusanBusan, South KoreaTaking people
- Gyeonggi-doGyeonggi-do, South KoreaTaking people
- JeollanamJeollanam, South KoreaTaking people
- Seongnam-siSeongnam-si, South KoreaTaking people
- SeoulSeoul, South KoreaTaking people
- SuwonSuwon, South KoreaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Novartis Pharmaceuticals
- Trial code
- NCT06514521
- Record updated
- 6 July 2026
- Original description
Post marketing study on Pluvicto in KoreaRead full original descriptionShow less
A Post Marketing Surveillance on PluvictoTM (Lutetium(177Lu) Vipivotide Tetraxetan) in South Korea; An Open-label, Non-interventional, Primary Data Collection, Multi-center, Non-comparative, Non-randomized Observational Study to Assess Safety and Effectiveness of Pluvicto in Real World Setting
Post marketing study on Pluvicto in Korea
Inclusion: Study participants eligible for inclusion in this study must meet all of the following criteria:; Male adult patient age ≥ 18; Subject who are being treated with Pluvicto or whose treatment plan is finalized and scheduled to be administered at the time of consent by physician in accordance with the approved indication in South Korea; Subject who provided the written informed consent prior to the study enrollment.
Exclusion: Study participants meeting any of the following criteria are not eligible for inclusion in this study:; Subject whose medical record is not accessible; Subject who is not willing to provide the informed consent.